IMRN - Immuron Inc Company Cash on Hand

IMRN (Immuron Limited) - company brandmark

Immuron Limited is developing innovative gastrointestinal treatments in collaboration with the U.S. Department of Defense. The niche status of antibodies used to combat diarrhea allows for flexible pricing power. However, marketing expenses and FDA expectations are creating financial pressure. The cash balance history demonstrates current liquidity, where the value is maintained at 0.01, helping to assess the company's resilience.

Company Cash Funds: Immuron Limited (IMRN) for 07/04/2022 - 11/21/2026

Metric breakdowns and analytics for Immuron Limited (IMRN)

- stock value and consensus price forecast:
Basic company analysis:Immuron IMRN
Signature product of Immuron Inc

This indicator measures the volume of liquid assets of Immuron Limited (IMRN), allowing for a real-time assessment of the company's solvency and financial cushion. The current cash level stands at 0.01, which is critical for ensuring the commercial scaling of drugs through pharmacy chains and optimizing operating expenses during production expansion, confirming the resilience of the issuer's investment profile.